The global biomarkers market is expected to grow at a CAGR of 9.9% in the first half of the forecast period. In 2018, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 48% of the global biomarkers market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 170-page report you will receive 104 charts– all unavailable elsewhere.
The 170-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Biomarkers Market forecasts to 2029
• This report also breaks down the revenue forecast for the global biomarkers market by Product: • Consumables • Services • Software
• This report also breaks down the revenue forecast for the global biomarkers market by Sector: • Biomarker Services • Biomarker Diagnostics • Biomarker Discovery
• This report also breaks down the revenue forecast for the global biomarkers market by Type: • Safety Biomarkers • Efficacy Biomarkers • Validation Biomarkers
• This report also breaks down the revenue forecast for the global biomarkers market by Discipline: • Genomics • Proteomics • Bioinformatics • Other
• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication: • Cancer • Cardiovascular Diseases • CNS • Autoimmune Diseases • Other
• This report provides individual revenue forecasts to 2029 for these regional and national markets: • North America: US, Canada • Europe: Germany, UK, France, Spain, Italy, Rest of Europe • Asia-Pacific: China, Japan, India, Australia, South Korea, Rest of APAC • Middle East & Africa: South Africa, Saudi Arabia, Rest of Middle East & Africa • Latin America: Brazil, Mexico, Rest of Latin America
• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers: • AB SCIEX • Agilent • Axela Inc • Caprion Proteomics • Charles River Laboratories • Critical Diagnostics • Epigenomics • Genomic Health • ICON plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec
• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca
• Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are their prospects over the forecast period?
Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Biomarkers: World Market Overview 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Key Questions Answered by This Analytical Report Include 1.5 Who is this report for? 1.6 Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. An Introduction to Biomarkers 2.1 Definition of a Biomarker 2.1.1 A Brief History of Biomarkers 2.1.2 The Importance of Biomarkers 2.2 Biomarker Discovery and Validation 2.3 Uses of Biomarkers 2.3.1 Assessing Drug Efficacy 2.3.2 Assessing Drug Safety 2.3.3 Companion Diagnostics 2.3.4 Therapeutic Importance of Biomarkers 2.3.5 Imaging Biomarkers 2.4 Biomarkers and Personalised Medicine 2.5 Biomarker Discovery 2.5.1 Genomics 2.5.2 Proteomics 2.5.3 Metabolomics
3.The World Biomarkers Market Forecast to 2029 3.1 The World Biomarkers Market, 2018 3.1.1 The World Biomarkers Market: Overall Revenue Forecast to 2029 3.1.2 Lack of Investment and Reimbursement Issues May Restrain Market 3.2 The World Biomarkers Market by Product, 2018 3.2.1 The World Biomarkers Market by Product, 2018-2029 3.3 The World Biomarkers Market by Sector, 2018 3.3.1 The World Biomarkers Market by Sector, 2018-2029 3.4 The World Biomarkers Market by Type, 2018 3.4.1 The World Biomarkers Market by Type, 2018-2029 3.5 The World Biomarkers Market by Discipline, 2018 3.5.1 The World Biomarkers Market by Discipline, 2018-2029
4. Leading Disease Indications for Biomarker Discovery and Development: Forecast to 2029 4.1 The World Biomarkers Market by Disease Indication, 2018 4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2018-2029 4.3 Cancer Biomarker Market 4.3.1 A Brief History of Cancer Biomarker Research 4.3.2 The Current State of Cancer Biomarker Research 4.3.3 Companion Diagnostics for Cancer 4.3.4 Initiatives in Cancer Biomarker Research 4.3.4.1 Cancer Genome Atlas 4.3.4.2 The Early Detection Research Network 4.3.5 Many Cancer Diagnostics Are Reaching the Market 4.3.6 Opportunities and Challenges for Cancer Biomarkers 4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2018-2029 4.4 Cardiovascular Disease Biomarker Submarket 2018 4.4.1 A Brief History of Cardiovascular Biomarker Research 4.4.2 The Current State of Cardiovascular Disease Biomarker Research 4.4.3 Cardiovascular Disease Diagnostics 4.4.4 Collaborations in Cardiac Biomarker Research 4.4.5 The Future of Cardiovascular Biomarker Research 4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2018-2029 4.5 CNS Diseases Biomarker Submarket, 2018 4.5.1 The Current State of CNS Disease Biomarker Research 4.5.2 Initiatives in CNS Disease Biomarker Research 4.5.3 Biomarker-Based Diagnostics for CNS Diseases 4.5.3 Biomarker-Based Diagnostics for CNS Diseases 4.5.3.1 ADtect (DiaGenic) 4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare) 4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly) 4.5.3.4 Flutemetamol (GE Healthcare) 4.5.3.5 Florbetaben (Piramal Imaging) 4.5.4 CSF Biomarkers 4.5.5 Alzheimer’s Disease: Beyond Amyloid Beta 4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer’s Disease 4.5.6 Multiple Sclerosis: Search for Disease Biomarker 4.5.7 Parkinson’s Disease: Effective Biomarker Yet to be Discovered 4.5.7.1 Fluid-Based Biomarker Discovery 4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2018-2029 4.6 Autoimmune Disease Biomarker Submarket, 2018 4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease 4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease 4.6.2.1 Ventra DA – Myriad Genetics 4.6.2.2 NavigAID SSc – Protagen AG 4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer 4.6.3 Increasing consolidation within the market 4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders 4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics 4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2018-2029 4.7 Growth in Key Biomarker Indications, 2018-2029
5. Leading National Biomarker Markets Forecast to 2029 5.1 The World Biomarkers Market: Regional Breakdown, 2018 5.2 The World Biomarkers Market: Regional Forecast, 2018-2029 5.3 North America Biomarkers Market, 2018-2029 5.4 Europe Biomarker Markets, 2018-2029 5.5 Asia-Pacific Biomarker Market, 2018-2029 5.6 Latin America Biomarker Market, 2018-2029 5.7 Middle East & Africa Biomarker Market, 2018-2029
6. Biomarker Industry Trends 6.1 Strengths and Weaknesses of the Biomarkers Market, 2018 6.2 Opportunities and Threats in the Biomarkers Market, 2018-2029 6.3 STEP Analysis of The World Biomarkers Market 6.4 Social Factors 6.4.1 Patient Stratification: Striving Towards Personalised Medicine 6.4.2 Biomarker Hype May Not Always Lead to New Discoveries 6.4.3 Growing Emphasis on Oncology for Companies 6.5 Technological Factors 6.5.1 Decreasing Size, Increasing Sensitivity 6.5.1.1 ABT Molecular Imaging 6.5.2 The Need for More-Efficient Data Storage 6.6 Economic Factors 6.6.1 Biomarkers: Cutting the Cost of Drug Development 6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures 6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups 6.6.3 Outsourcing Biomarker Discovery and Development 6.7 Political Factors 6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery 6.7.2 Improving Regulatory Guidelines to Speed Development 6.7.3 Concerns Over Biomarker Patenting Hits Innovation 6.8 Challenges in Developing Biomarkers 6.9 Combining Drug and Diagnostic Development 6.10 MicroRNA Biomarkers: A Prospective Target? 6.11 Big Pharma and Biomarkers 6.11.1 Pfizer 6.11.2 Novartis 6.11.3 Merck & Co. 6.11.4 Sanofi 6.11.5 Roche 6.11.5.1 Roche Diagnostics 6.11.5.2 Ventana Medical Systems 6.11.6 GSK 6.11.7 AstraZeneca 6.11.8 Abbott Laboratories
7. Leading Companies in the Biomarkers Market 7.1 Biomarker Service Providers 7.1.1 Global CROs and Biomarkers 7.1.1.1 Not All Global CROs Are Investing in Biomarkers 7.1.2 Quintiles IMS Holdings Inc. 7.1.2.1 Quintiles and IMS Health Merger 7.1.3 Laboratory Corporation of America Holdings 7.1.3.1 LabCorp Diagnostics 7.1.3.2 Covance Drug development 7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2017 7.1.4 PAREXEL International Corp. 7.1.5 Charles River Laboratories 7.1.6 ICON plc 7.1.7 WuXi PharmaTec 7.1.8 Caprion Proteomics 7.1.9 Proteome Sciences 7.1.10 Pacific Biomarkers 7.1.11 Oxford Gene Technology 7.1.12 Worldwide Clinical Trials 7.2 Biomarker Technology Providers 7.2.1 Agilent 7.2.1.1 Diagnostics and Biomarker Assays 7.2.1.2 Growing Asian Markets: Focus on South Korea 7.2.2 AB SCIEX 7.2.2.1 Partnership with Illumina, OneOmics project 7.2.3 QIAGEN 7.2.4 ANGLE Biosciences, Inc. (Axela) 7.2.5 Thermo Fisher Scientific 7.2.5.1 Strategic Acquisitions 7.2.5.2 Research Collaborations 7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre 7.3 Biomarker Diagnostic Developers 7.3.1 Quest Diagnostics 7.3.1.1 Acquisitions to expand the product portfolio and geographic presence 7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc. 7.3.2 Myriad Genetics 7.3.2.1 Pipeline 7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic 7.3.2.3 Strategic Acquisitions 7.3.2.4 Myriad RBM 7.3.3 Genomic Health 7.3.3.1 Collaborations with Epic Sciences and Biocartis 7.3.4 Critical Diagnostics 7.3.5 Epigenomics 7.3.5.1 Diagnostic Product Portfolio 7.3.6 MDxHealth 7.3.6.1 Diagnostic Product Portfolio and Pipeline
8. Conclusions 8.1 State of the World Biomarkers Market in 2018 8.2 Growth in the World Biomarkers Market, 2018-2029 8.2.1 Dominance of Leading Western Markets 8.3 The Use of Biomarkers in Drug Discovery and Development 8.4 Demand for New Diagnostics
Appendices Associated Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2018 Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016 Table 2.3 Technologies and Platforms for Biomarker Research, 2018 Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Product, 2018 Table 3.2 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Product, 2018-2029 Table 3.3 World Biomarkers Market: Market Shares (%) by Product, 2018, 2023, 2029 Table 3.4 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2018 Table 3.5 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2018-2029 Table 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2018, 2023, 2029 Table 3.7 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Type, 2018 Table 3.8 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Type, 2018-2029 Table 3.9 World Biomarkers Market: Market Shares (%) by Type, 2018, 2023, 2029 Table 3.10 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2018 Table 3.11 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2018-2029 Table 3.12 World Biomarkers Market: Market Shares (%) by Discipline, 2018, 2023, 2029 Table 4.1 World Biomarkers Market: Market Share (%) by Disease Indication, 2018 Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Disease Indication, 2018-2029 Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2018 Table 4.4 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 4.5 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 4.6 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 4.7 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 4.8 World Biomarkers Market: Market Share (%) by Disease Indication, 2018, 2023 and 2029 Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2018 Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Region, 2018-2029 Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2018, 2023, 2029 Table 5.4 North America Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 5.5 Europe Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2018 Table 5.6 Europe Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2018-2029 Table 5.7 Asia-Pacific Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2018-2029 Table 5.8 Latin America Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 5.9 Middle East & Africa Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029 Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2018-2029 Table 6.2 World Biomarkers Market: Opportunities and Threats, 2018-2029 Table 6.3 World Biomarkers Market: STEP Analysis, 2018-2029 Table 6.4 US Cancer Deaths by Tumour Type, 2018 Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2018 Table 6.6 PSTC Biomarkers in Development, 2018 Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015 Table 6.8 IMI-Funded Biomarker Projects Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2016-2017 Table 7.2 Proteome Sciences: Revenue ($mn), 2016-2017 Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2017 Table 7.4 Company Revenue by Sector ($mn), 2017 Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2017 Table 7.6 Genomic Health: Revenue by Division ($mn), 2016-2017 Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2016-2017 Table 7.8 MDx Health: Revenue by Source ($mn), 2016-2017 Table 7.9 MDxHealth: Pipeline, 2017 Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2018, 2023 and 2029 Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Discipline, 2018-2023 and 2029 Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease Indication, 2018, 20123 and 2029 Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Product, 2018, 2023 and 2029 Table 8.5 World Biomarkers Market: Revenues ($bn, CAGR %) by Type, 2018, 2023 and 2029 Table 8.6 World Biomarkers Market: Revenues ($bn, CAGR %) by Region, 2018, 2023 and 2029
List of Figures Figure 2.1 Definitions of a Biomarker, 2018 Figure 2.2 The Biomarker Discovery and Validation Process, 2018 Figure 3.1 World Biomarkers Market: Drivers and Restraints, 2018-2029 Figure 3.2 World Biomarkers Market: Market Shares (%) by Product, 2018 Figure 3.3 World Biomarkers Market by Product: Market Forecast ($bn), 2018-2029 Figure 3.4 World Biomarkers Market: Market Shares (%) by Product, 2023 Figure 3.5 World Biomarkers Market: Market Shares (%) by Product, 2029 Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2018 Figure 3.7 World Biomarkers Market by Sector: Market Forecast ($bn), 2018-2029 Figure 3.8 World Biomarkers Market: Market Shares (%) by Sector, 2023 Figure 3.9 World Biomarkers Market: Market Shares (%) by Sector, 2029 Figure 3.10 World Biomarkers Market: Market Shares (%) by Type, 2018 Figure 3.11 World Biomarkers Market by Type: Market Forecast ($bn), 2018-2029 Figure 3.12 World Biomarkers Market: Market Shares (%) by Type, 2023 Figure 3.13 World Biomarkers Market: Market Shares (%) by Type, 2029 Figure 3.14 World Biomarkers Market: Market Shares (%) by Discipline, 2018 Figure 3.15 World Biomarkers Market, by Discipline: Market Forecast ($bn), 2018-2029 Figure 3.16 World Biomarkers Market: Market Shares (%) by Discipline, 2023 Figure 3.17 World Biomarkers Market: Market Shares (%) by Discipline, 2029 Figure 4.1 World Biomarkers Market: Market Share (%) by Disease Indication, 2018 Figure 4.2 Cancer Submarket: Revenue Forecast ($bn), 2018-2029 Figure 4.3 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2018-2029 Figure 4.4 CNS Diseases Submarket: Revenue Forecast ($bn), 2018-2029 Figure 4.5 Autoimmune Diseases Submarket: Revenue Forecast ($bn), 2018-2029 Figure 4.6 World Biomarkers Market: Market Share (%) by Disease Indication, 2023 Figure 4.7 World Biomarkers Market: Market Shares (%) by Disease Indication,2029 Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2018 Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2023 Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2029 Figure 5.4 North America Biomarkers Market: Revenue Forecast ($bn), 2018-2029 Figure 5.5 Europe Biomarker Markets: Market Share (%) by Country, 2018 Figure 5.6 Europe Biomarker Markets: Revenue Forecasts ($bn), 2018-2029 Figure 5.7 Asia-Pacific Biomarker Market: Revenue Forecasts ($bn), 2018-2029 Figure 5.8 Latin America Biomarker Market Revenue Forecast ($bn), 2018-2029 Figure 5.9 Middle East & Africa Biomarker Market Revenue Forecast ($bn), 2018-2029 Figure 6.1 US Cancer Deaths by Tumour Type, 2018 Figure 6.2 Average Cost of Sequencing the Human Genome ($m), 2005-2015 Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2016-2017 Figure 7.2 Proteome Sciences: Revenue ($mn), 2016-2017 Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2017 Figure 7.4 Genomic Health: Product Revenue ($mn), 2016-2017 Figure 7.5 Epigenomics Revenue ($mn), 2016-2017 Figure 7.6 MDx Health: Revenue by Source ($mn), 2016-2017 Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2018, 2023 and 2029 Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027 Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease Indication, 2018, 2023 and 2029 Figure 8.4 World Biomarkers Market: Revenues ($bn) by Product, 2018, 2023 and 2029 Figure 8.5 World Biomarkers Market: Revenues ($bn) by Type, 2018, 2023 and 2029 Figure 8.6 World Biomarkers Market: Revenues ($bn) by Country, 2018, 2023 and 2029
454 Life Sciences AB SCIEX Abbott Laboratories Abbott Molecular Abcodia ABT Molecular Imaging ACS Biomarker Advanced Cell Diagnostics (ACD) Advion Bioanalytical Labs (part of Quintiles) Affymetrix Agendia Agilent Alacris Theranostics Alere Amarantus BioSciences Amgen Applied Biosystems (part of Life Technologies) Aptiv Solutions Arctic Partners ARIAD Pharmaceuticals Ariana Pharma Arizona State University Arrayit ARUP Laboratories AstraZeneca Athena Diagnostics (a subsidiary of Quest Diagnostics) Atherotech Diagnostics Lab Aushon Biosystems Axela Inc Bayer Belfer Institute for Applied Cancer Science [US] Berkeley HeartLab (a subsidiary of Quest Diagnostics) BG Medicine BGI (formerly Beijing Genomics Institute) Biofortis Biosoft BRAHMS (part of Thermo Fisher Scientific) Brigham and Women’s Hospital Bristol-Myers Squibb Cancer Research Technology Caprion Proteomics CBC (Comprehensive Biomarker Centre GmbH) Celera (part of Quest Diagnostics) Celgene Cell Signaling Technology Celldex Therapeutics Cephalon (part of Teva) Charles River Laboratories Chronix Biomedical Chugai Pharmaceutical Ciphergen Biosystems Clarient Diagnostic Services Cleveland HeartLab Clinigene International Comprehensive Biomarker Center (formerly Febit) Covance Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita Labs DiaGenic Durin Technologies DxS (now part of QIAGEN) EKO Diagnostic Eli Lilly and Co. Epic Sciences Epigenomics Epistem EQT Evotec Exact Sciences Exiqon Exonhit Ezose Sciences (part of Shionogi) FEI Company Foundation Medicine Fujirebio Diagnostics GE Healthcare Genetic Technologies Geneva Bioinformatics (GeneBio) Genomic Health GenWay Biotech Great Point Partners GSK HD Biosciences Health Diagnostic Laboratory HealthLinx Helicos BioSciences Hewlett-Packard HTG Molecular Diagnostics ICON Plc Illumina ImmunId Insight Genetics Institute of Pathology Heidelberg (IPH) Integrated Diagnostics Ipsen Ipsogen (a subsidiary of QIAGEN) Isogen Life Science Johnson & Johnson (J&J) KU Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co. Merck KGaA Metabolon Michael J Fox Foundation Myriad Genetics Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics) National Academy of Sciences (NAS) [US] Nephromics Novartis Novartis Molecular Diagnostics (part of Novartis) NovioGendix Oncoimmune Oncomedics OpGen OPKO Health Orion Genomics Oxford Cancer Biomarkers Oxford Gene Technology Pacific Biomarkers Pacific Biosciences Panomics (now part of Affymetrix) Parexel Patheon Pathwork Diagnostics Personal Genome Diagnostics Pfizer Pierre Fabre PLUS Diagnostics PMDA Power3 Medical Products PPD Predictive Biosciences Prometheus Laboratories ProtagenAG Proteome Sciences QIAGEN QLIDA Diagnostics Quanterix Quanticel Pharmaceuticals Quest Diagnostics Quintiles Quintiles IMS Holdings Inc Randox Laboratories Randox Laboratories Roche SABiosciences (now part of QIAGEN) Sandor Proteomic Sanger Institute Sanofi Santaris Pharma Servier Shionogi Siemens Siemens Healthcare Singulex Inc Sividion Diagnostics SMA Foundation [US] Stemina Biomarker Discovery Sysmex Technology Strategy Board (TSB) [UK] Teva Pharmaceutical Industries Thallion Pharmaceuticals The Biomarkers Consortium Thermo Fisher Sciences Thermo Fisher Scientific Transgene Trans-Hit Biomarkers Tufts Center for the Study of Drug Development Ventana Medical Systems Vertex Pharmaceuticals WaferGen Warnex Worldwide Clinical Trials WuXi AppTec Wuxi Pharmatech Xcovery
List of Organizations Mentioned in the Report American College of Cardiology Foundation (ACCF) American Heart Association (AHA) Association for Molecular Pathology (AMP) [US] British Heart Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia] EMA (European Medicines Agency) ETH Zurich European Commission European Federation of Pharmaceutical Industries and Associations (EFPIA) European Medicines Agency (EMA) European Stroke Research Network for Hypothermia (Euro-HYP) Food and Drug Administration (FDA) [US] Hirosaki University Human Proteome Organisation (HUPO) International Cancer Genome Consortium (ICGC) Les entreprises du médicament (LEEM) [France] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [Germany] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National Human Genome Research Institute (NHGRI) [US] National Institute for Health and Clinical Excellence (NICE) [UK] National Institute of Allergy and Infectious Diseases (NIAID) [US] National Institute on Aging (NIA) [US] National Jewish Health [US] Newcastle University [UK] NIH (National Institute of Health) Oslo University Hospital Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical Devices Agency (PMDA) [Japan] Predictive Safety Testing Consortium (PSTC) [US] Shanghai Jiao Tong University Stanford University State Food and Drug Administration (SFDA) [China] Technion-Israel Institute of Technology University of Alabama University of Medicine and Dentistry of New Jersey (UMDNJ) University of Oslo University of Turku University of Washington Wellcome Trust Sanger Institute [UK] World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Biomarkers Market Forecast to 2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.
Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
